Global Acute Coronary Syndrome (ACS) Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Burden of Disease
06.3 Etiology
06.4 Pathophysiology
06.4.1 Myocardial Dysfunction
06.4.2 MI
06.4.3 Electrical Dysfunction
06.5 Prognosis
06.6 Epidemiology
06.6.1 Prevalence of Coronary Artery Disease
06.7 Diagnosis
06.7.1 ECG
06.7.2 Blood Tests
06.7.3 Nuclear Scan
06.7.4 CT
06.8 Management
07. ACS Pipeline Landscape
07.1 Key Pipeline Molecules
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by ECG Output
10 Geographical Segmentation
11 Buying Criteria
12 Market Growth Drivers
13 Drivers and their Impact
14 Market Challenges
15 Impact of Drivers and Challenges
16 Market Trends
17 Trends and their Impact
18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 AstraZeneca
18.2.2 Bristol-Myers Squibb
18.2.3 Eli Lilly
18.2.4 GlaxoSmithKline
18.2.5 Sanofi
18.3 Other Prominent Vendors
19 Key Vendor Analysis
19.1 AstraZeneca
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2011-2013
19.1.5 Revenue by Geography
19.1.6 Business Strategy
19.1.7 Key Developments
19.1.8 SWOT Analysis
19.2 Bristol-Myers Squibb
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Revenue by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Eli Lilly
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue
19.3.4 Revenue by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 GlaxoSmithKline
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Revenue by Geography
19.4.6 Pipeline Products
19.4.7 Business Strategy
19.4.8 Key Information
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Revenue by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20 Other Reports in this Series